               SEQUENCE LISTING

<110> Albert-Ludwigs-Universität Freiburg
      Novartis AG

<120> MDM2 INHIBITORS FOR USE IN THE TREATMENT OR PREVENTION OF HEMATOLOGIC NEOPLASM RELAPSE AFTER HEMATOPOIETIC CELL TRANSPLANTATION

<130> 2307/20WO

<150> EP 21184448.5
<151> 2021-07-08
<150> EP20197230.4
<151> 2020-09-21

<160> 16

<170> BiSSAP 1.3.6

<210> 1
<211> 22
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer forward hTrailR1

<400> 1
gtgtgggtta caccaatgct tc                                             22


<210> 2
<211> 22
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer reverse hTrailR1

<400> 2
cctggtttgc actgacatgc tg                                             22


<210> 3
<211> 21
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer forward hTrailR2

<400> 3
acagttgcag ccgtagtctt g                                              21


<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer reverse hTrailR2

<400> 4
ccaggtcgtt gtgagcttct                                                20


<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer forward CDKN1A

<400> 5
gtggctctga ttggctttct g                                              21


<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer reverse CDKN1A

<400> 6
ctgaaaacag gcagcccaag                                                20


<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer forward TNFRSF10A

<400> 7
ttcgcattcg gagttcaggg                                                20


<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer reverse TNFRSF10A

<400> 8
aagtggcaaa acgactccga                                                20


<210> 9
<211> 18
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer forward TNFRSF10B

<400> 9
acgactggtg cgtcttgc                                                  18


<210> 10
<211> 21
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer reverse TNFRSF10B

<400> 10
aagacccttg tgctcgttgt c                                              21


<210> 11
<211> 22
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer forward GAPDH

<400> 11
gtctcctctg acttcaacag cg                                             22


<210> 12
<211> 22
<212> DNA
<213> Artificial Sequence


<220> 
<223> Primer reverse GAPDH

<400> 12
accaccctgt tgctgtagcc aa                                             22


<210> 13
<211> 29
<212> RNA
<213> Artificial Sequence


<220> 
<223> TRAIL-R1 targeted shRNA

<400> 13
ttcgtctctg agcagcaaat ggaaagcca                                      29


<210> 14
<211> 29
<212> RNA
<213> Artificial Sequence


<220> 
<223> TRAIL-R2 targeted shRNA

<400> 14
agagacttgc caagcagaag attgaggac                                      29


<210> 15
<211> 29
<212> RNA
<213> Artificial Sequence


<220> 
<223> non-silencing shRNA control

<400> 15
gcactaccag agctaactca gatagtact                                      29


<210> 16
<211> 20
<212> RNA
<213> Artificial Sequence


<220> 
<223> Trail-R2 gRNA design

<400> 16
cgcggcgaca acgagcacaa                                                20


